- Home
- GNLX
GNLX
Genelux Corporation
as 03-28-2025 4:00pm EST
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec) and others.
| Founded: | 2001 | Country: | United States |
| Employees: | N/A | City: | WESTLAKE VILLAGE |
| Market Cap: | 184.4M | IPO Year: | 2023 |
| Target Price: | $18.25 | AVG Volume (30 days): | 172.7K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.94 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.60 - $6.50 | Next Earning Date: | 05-08-2025 |
| Revenue: | $8,000 | Revenue Growth: | -96.64% |
| Revenue Growth (this year): | -97.6% | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Genelux Corporation (GNLX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Tyree James L | GNLX | Director | Dec 30 '24 | Sell | $2.46 | 3,460 | $8,511.60 | 45,791 |
Latest Genelux Corporation News
GNLX Breaking Stock News: Dive into GNLX Ticker-Specific Updates for Smart Investing
MT Newswires
4 days ago
Genelux Announces FDA Guidance on Olvi-Vec Phase 3 Trial
MT Newswires
4 days ago
Genelux's Olvi-Vec Shows Anti-Tumor Effect in Phase 1b/2 Lung Cancer Study
MT Newswires
4 days ago
Genelux Prices $10.5 Million Stock Offering
GlobeNewswire
4 days ago
Genelux Corporation Announces Pricing of $10.5 Million Underwritten Offering of Common Stock
GlobeNewswire
4 days ago
Genelux and Newsoara Announce Positive Preliminary Phase 1b/2 Data of Olvi-Vec in Advanced Small-Cell Lung Cancer
GlobeNewswire
4 days ago
Genelux Announces Alignment with FDA on Key Elements of the Approval Pathway for Olvi-Vec in Platinum Resistant/Refractory Disease
Insider Monkey
a month ago
Why Genelux Corporation (GNLX) is Skyrocketing So Far in 2025
MT Newswires
2 months ago
Genelux Names Matthew Pulisic as CFO
Compare GNLX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "GNLX Genelux Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.